Inés Modrego‐Pardo

Insulin Injection Behaviors and Association with Glycemic Outcomes in Patients with Diabetes: A Real-World Survey in Spain

Alba Galdón Sanz-Pastor, Alicia Justel Enríquez, Ana Sánchez Bao, Rosa Pilar Quílez Toboso et autres

INTRODUCTION: Optimal glycemic control is essential to prevent complications in diabetes, and insulin administration practices play a key role. This study assessed insulin injection behaviors and related glycemic outcomes among individuals using multiple daily injections in Spain. METHODS: A cross-sectional online survey …

es (code pays fourni par la source)

Clinical Effectiveness of Oral Semaglutide in Women with Type 2 Diabetes: A Nationwide, Multicentre, Retrospective, Observational Study (Women_ENDO2S-RWD Substudy)

Rebeca Reyes‐García, Óscar Moreno, C. Guillén, Inés Modrego‐Pardo et autres

Background: Sex differences in type 2 diabetes (T2D) are a growing area of diabetes research. No data have been reported on sex differences with oral semaglutide (oSEMA) in a real-world setting. Methods: We included people with T2D who started treatment with oSEMA …

es (code pays fourni par la source)

Effects of oral semaglutide on kidney outcomes in people with type 2 diabetes: a nationwide, multicentre, retrospective, observational study (Renal_ENDO2S-RWD substudy)

Óscar Moreno, Rebeca Reyes‐García, C. Guillén, Viyey Doulatram‐Gamgaram et autres

Background: Subcutaneous semaglutide has shown kidney-protective effects in people with type 2 diabetes (PWT2D), but data on oral semaglutide remain limited. This multicentre real-world study evaluates the clinical effectiveness of oral semaglutide on kidney outcomes in PWT2D. Methods: We included PW2TD ≥18 …

es (code pays fourni par la source)

Trans and cis women in sport: Citius, altius, fortius, sed aequitas

Inés Modrego‐Pardo

es (code pays fourni par la source)

Mujeres trans y cis en el deporte: citius, altius, fortius, sed aequitas

Inés Modrego‐Pardo

es (code pays fourni par la source)

Psychological assessment and counseling remain important features of quality care: A descriptive study of individuals who did not start gender-affirming medical treatment in a gender identity unit in Spain

Pablo Expósito-Campos, Marcelino Gómez Balaguer, Felipe Hurtado Murillo, Pablo Fernández Collazo et autres

Not all individuals referred to gender identity units receive gender-affirming medical treatment (GAMT). However, there is a paucity of literature examining the reasons for this. This study aimed to investigate the reasons for not initiating GAMT in individuals who initially reported gender …

es (code pays fourni par la source)

Psychological assessment and counseling remain important features of quality care: A descriptive study of individuals who did not start gender-affirming medical treatment in a gender identity unit in Spain

Pablo Expósito-Campos, Marcelino Gómez Balaguer, Felipe Hurtado Murillo, Pablo Fernández Collazo et autres

Not all individuals referred to gender identity units receive gender-affirming medical treatment (GAMT). However, there is a paucity of literature examining the reasons for this. This study aimed to investigate the reasons for not initiating GAMT in individuals who initially reported gender …

es (code pays fourni par la source)

Are we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney disease?

Óscar Moreno, Rebeca Reyes‐García, Inés Modrego‐Pardo, Marina López-Martínez et autres

We are entering a new era in the management of adiposity-based chronic disease (ABCD) with type 2 diabetes (T2D) and related chronic kidney disease (CKD). ABCD, T2D and CKD can affect almost every major organ system and have a particularly strong impact …

es (code pays fourni par la source)

Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study ( ENDO 2 S‐RWD )

Óscar Moreno, Rebeca Reyes‐García, Inés Modrego‐Pardo, Viyey Doulatram‐Gamgaram et autres

BACKGROUNDType 2 diabetes guidelines recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and/or sodium-glucose co-transporter-2 inhibitors for people living with type 2 diabetes (PLWT2D) with an Oscar Moreno-Pérez and Rebeca Reyes-Garcia have contributed equally to this work and share the first authorship.

es (code pays fourni par la source)

Author response for "Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study ( ENDO2S‐RWD )"

Rebeca Reyes‐García, Inés Modrego‐Pardo, Viyey Doulatram‐Gamgaram, Carlos Casado Cases et autres

Author response for "Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study ( ENDO2S‐RWD )"

Rebeca Reyes‐García, Inés Modrego‐Pardo, Viyey Doulatram‐Gamgaram, Carlos Casado Cases et autres

THU283 Oral Semaglutide, Effectiveness, Safety And Tolerability In Real Life: A Short-term Retrospective Observational Study

Óscar Moreno, Cristina Guillén-Morote, Thalía Argüello, Carmen Soriano et autres

Abstract Disclosure: O. Moreno-Perez: None. C. Guillen-Morote: None. T. Argüello: None. C. Soriano: None. E. SantaCruz: None. P. Lopez-Mondejar: None. C. Navarro-Hoyas: None. R. Sanchez-Ortiga: None. M. Sanchez-Pacheco: None. I. Modrego-Pardo: None. A.M. Pico: None. Introduction: Oral semaglutide (oSEMA) is the first …

es (code pays fourni par la source)